Volume 11, Number 10, October 2005

Botulinum Neurotoxin Detection and Differentiation by Mass Spectrometry

John R. Barr,* Hercules Moura,* Anne E. Boyer,* Adrian R. Woolfitt,* Suzanne R. Kalb,* Antonis Pavlopoulos,* Lisa G. McWilliams,† Jurgen G. Schmidt,‡ Rodolfo A. Martinez,‡ and David L. Ashley*
*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Battelle Memorial Institute, Atlanta, Georgia, USA; and ‡Los Alamos National Laboratory, Los Alamos, New Mexico, USA

Figure 3. High-performance liquid chromatography–electrospray ionization-tandem mass spectrometry chromatogram showing the botulinum neurotoxin (BoNT)-A substrate and product ions (CT, C-terminal; NT, N-terminal) from a reaction with 25 mouse lethal dose (MLD)₅₀ BoNT-A. Each peptide has both a quantification ion (top trace) and a verification ion (lower trace). Isotopically labeled standards are added (traces not shown) as internal standards for quantification. The labeled peptides co-elute with their nonlabeled counterparts and are distinguishable by mass. Leucine enkephalin was included as a secondary reference compound and only 1 ion was monitored.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed September 15, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention